Toby
Research Tear Sheet: Village Farms International (VFF) stock
Last year, Canada became the breeding ground for numerous pot stocks following the country’s decision to legalize the use of…
Is Lululemon’s bull run coming to an end?
Lululemon Athletica (NASDAQ: LULU) is one apparel brand that has been cruising despite the onslaught of online shopping giants. Since…
Wall St expecting a turn-around quarter from Rite Aid in Q2
Things haven’t been working out so well for Rite Aid (NYSE: RAD) since the past three years. The company’s inability…
Alexion Pharmaceuticals could still be a valuable addition to your portfolio
Biopharmaceutical firm Alexion Pharmaceuticals (NASDAQ: ALXN) has been going through a volatile phase lately. The company was expected to be…
Cracker Barrel ends fiscal 2019 with strong growth
Restaurant chain Cracker Barrel Old Country Store, Inc. (NASDAQ: CBRL) on Tuesday reported a 2.9% decline in fourth-quarter sales to…
US energy stocks gain from oil field destruction at Aramco
The weekend greeted us with the grim news of drone strikes at the oil fields of Saudi Aramco, which wiped…
CannTrust may be cheap, but stay away from this pot stock
Shares of CannTrust Holdings (NYSE: CTST) have plunged over 80% in the past 12 months, making it quite cheap with…
Aurora, Canopy Growth to be the biggest gainers in Cannabis 2.0
Both Aurora Cannabis (NYSE: ACB) and Canopy Growth Corporation (NYSE: CGC) have reported disappointing quarterly results in the most recent…
Ban threat looming large over e-cigarette industry
In the backdrop of six fatalities in the US relating to vaping, the Donald Trump administration may soon impose a…
Square takes a hit as JPMorgan Chase launches same-day deposits
In a move that could wreck the market equations in the payment processing market, banking giant JPMorgan Chase (NYSE: JPM)…
Preview: How to play CrowdStrike Holdings Q2 earnings
Cybersecurity firm CrowdStrike (NASDAQ: CRWD) has twice impressed the Wall Street so far. The first time was when it went public…
Novartis scores another point in multiple sclerosis therapy, stock rises
Swiss pharmaceutical giant Novartis International AG (NYSE: NVS) on Friday said its ofatumumab met the primary and secondary endpoints of…